Poll Ev Questions

D

What part of an enzyme binds to the substrate?

A) Initiation site

B) Substrate site

C) Transformation site

D) Active Site

E) Energy Site

B

Which of the following statements is FALSE?

A) The shape of the active site is determined by the amino acid sequence of the enzyme

B) The shape of the active site is constantly changing, allowing the enzyme to bind to many different substances

C) When a substrate encounters the active site of its enzyme, the substrate and enzyme become held together by weak chemical bonds.

D) The active site of an enzyme is specific, recognizing only 1 particular substrate.

A

One function of the normal ABL kinase is to phosphorylate substrates that tell white blood cells to grow and divide. the ABL kinase is mutated in CML, giving rise to the BCR-ABL protein. Based on the normal function of ABL in white blood cells, how do you think the mutated version of the kinase (BCR-ABL) contributes to the development of CML, a cancer of the white blood cells?

A) The kinase becomes overactive (too much enzyme activity)

B) The kinase becomes inactive (too little or no enzyme activity)

C) The activity stays the same

C

Predict the mechanism of action of Gleevec. Which of the following mechanisms would best treat Tony's cancer?

A) Gleevec inhibits the function of all kinase enzymes

B) Gleevec promotes the function of all kinase enzymes

C) Gleevec inhibits the function of the BCR-ABL kinase

D) Gleevec promotes the function of the BCR-ABL kinase

B

What type of inhibitor is Gleevec?

A) Non-competitive inhibitor, binding to the ATP site

B) Competitive inhibitor, binding to the ATP site

C) Non-competitive inhibitor, binding to substrate binding site

D) Competitive inhibitor, binding to substrate binding site

C

Predict what would happen to Tony's white blood cell count if he stopped taking Gleevec.

A) His white blood cell count would stay within the normal and healthy range

B) His white blood cell count would drop below the normal and healthy range

C) His white blood cell count would rapidly increase above the normal and healthy range

B

What type of inhibitor is dasatinib?

A) non-competitive inhibitor, binding to the ATP site

B) competitive inhibitor, binding to the ATP site

C) non-competitive inhibitor, binding to substrate binding site

D) competitive inhibitor, binding to substrate binding site